Neximmune Stock Return On Asset
| NEXIDelisted Stock | USD 2.43 0.22 9.95% |
Neximmune fundamentals help investors to digest information that contributes to Neximmune's financial success or failures. It also enables traders to predict the movement of Neximmune Pink Sheet. The fundamental analysis module provides a way to measure Neximmune's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Neximmune pink sheet.
Neximmune |
Neximmune Company Return On Asset Analysis
Neximmune's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Neximmune Return On Asset | -0.7 |
Most of Neximmune's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neximmune is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
CompetitionBased on the latest financial disclosure, Neximmune has a Return On Asset of -0.6971. This is 92.03% lower than that of the Biotechnology sector and 97.05% lower than that of the Health Care industry. The return on asset for all United States stocks is notably higher than that of the company.
Neximmune Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neximmune's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Neximmune could also be used in its relative valuation, which is a method of valuing Neximmune by comparing valuation metrics of similar companies.Neximmune is currently under evaluation in return on asset category among its peers.
Neximmune Fundamentals
| Return On Equity | -1.96 | ||||
| Return On Asset | -0.7 | ||||
| Current Valuation | (491.95 K) | ||||
| Shares Outstanding | 1.37 M | ||||
| Shares Owned By Insiders | 17.00 % | ||||
| Shares Owned By Institutions | 11.17 % | ||||
| Number Of Shares Shorted | 15.99 K | ||||
| Price To Book | 1.38 X | ||||
| EBITDA | (28.17 M) | ||||
| Net Income | (32.34 M) | ||||
| Cash And Equivalents | 53.13 M | ||||
| Cash Per Share | 2.20 X | ||||
| Total Debt | 68.81 K | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 6.54 X | ||||
| Book Value Per Share | 2.00 X | ||||
| Cash Flow From Operations | (31.43 M) | ||||
| Short Ratio | 2.26 X | ||||
| Earnings Per Share | (24.11) X | ||||
| Target Price | 2.0 | ||||
| Beta | 1.94 | ||||
| Market Capitalization | 3.25 M | ||||
| Total Asset | 8.59 M | ||||
| Retained Earnings | (222.59 M) | ||||
| Working Capital | 316.73 K | ||||
| Net Asset | 8.59 M |
About Neximmune Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Neximmune's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neximmune using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neximmune based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Other Consideration for investing in Neximmune Pink Sheet
If you are still planning to invest in Neximmune check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neximmune's history and understand the potential risks before investing.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |